arrhythmogenic cardiomyopathy

source: pixabay.com

RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

Post author:Jessica Lynn
Post published:June 20, 2023
Post category:Arrhythmogenic right ventricular dysplasia PKP2 arrhythmogenic cardiomyopathy

Gene therapy has the potential to improve outcomes among individuals across various disease spectrums. In the case of clinical-stage biotechnology company Rocket Pharmaceuticals, the company is working to develop…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More